Core Insights - BeOne Medicines showcases its leadership in B-cell malignancies at the ASH 2025 conference, presenting extensive new data from its hematology portfolio, including BRUKINSA, sonrotoclax, and BGB-16673 [1][3][4] Group 1: BRUKINSA (Zanubrutinib) - BRUKINSA demonstrates sustained overall survival of 84% and 88% after COVID adjustment, with a landmark progression-free survival (PFS) superiority of 74% at 6 years in treatment-naïve chronic lymphocytic leukemia (CLL) [5] - Long-term data from the SEQUOIA and ALPINE studies confirm BRUKINSA's role as the backbone of CLL therapy, with continuous treatment showing clinically meaningful benefits [6][11] - BRUKINSA is positioned as the preferred BTK inhibitor due to its manageable side effect profile, including lower incidences of fatigue and pain compared to other treatments [8] Group 2: Sonrotoclax - Sonrotoclax, a next-generation BCL2 inhibitor, shows promising clinical activity in B-cell malignancies, with early trials indicating rapid undetectable minimal residual disease (uMRD) rates in treatment-naïve CLL patients [22][23] - The FDA has granted Breakthrough Therapy Designation for sonrotoclax in relapsed or refractory mantle cell lymphoma (MCL) and Fast Track Designation for MCL and Waldenström macroglobulinemia [24] Group 3: BGB-16673 - BGB-16673 is a potential first-in-class BTK protein degrader, with nearly 800 patients dosed in clinical trials, including three Phase 3 trials in relapsed/refractory CLL [25][26] - The drug is designed to degrade both wildtype and mutant forms of BTK, addressing resistance issues seen in patients with progressive disease [25] Group 4: Clinical Presentations and Data - Nearly 50 abstracts accepted for presentation at ASH 2025, including six oral presentations highlighting the efficacy and safety of BeOne's hematology assets [1][4] - Presentations will include real-world evidence and modeling approaches to refine understanding of treatment outcomes with BTK inhibitors [7][20] Group 5: Company Overview - BeOne Medicines is a global oncology company focused on developing innovative treatments for cancer, with a commitment to improving access to medicines for patients worldwide [32][33]